Needham Maintains Buy on Cytokinetics, Raises Price Target to $102
Benzinga Newsdesk 6 months ago
NewsPrice TargetAnalyst Ratings
Needham analyst Serge Belanger maintains Cytokinetics (NASDAQ:CYTK) with a Buy and raises the price target from $85 to $102.
Needham analyst Serge Belanger maintains Cytokinetics (NASDAQ:CYTK) with a Buy and raises the price target from $85 to $102.